

FORBIUS

Forbius to Present at the 37th Annual J.P. Morgan Healthcare Conference

Austin, TX and Montreal, QC (Jan. 2, 2019) – Forbius, a clinical-stage company developing biologics for the treatment of fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting at the [37th Annual J.P. Morgan Healthcare Conference](#).

Mr. Tikhomirov's presentation will take place Wednesday, January 9th at 11:30 a.m. PST in Elizabethan D at the Westin St. Francis Hotel in San Francisco.

About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Forbius is a clinical stage protein engineering company that designs, develops, and commercializes biotherapeutics for the treatment of fibrosis and cancer. Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Our lead program targeting the TGF-beta pathway is AVID200. AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor. This TGF-beta isoform selectivity was chosen in order to achieve an optimal therapeutic index. The AVID200 program has been cleared by the FDA for two Phase 1b clinical trials in fibrotic indications, as well as a Phase 1 clinical trial in solid tumors. Additional clinical trials in fibrotic indications are planned for 2019.

Forbius' lead program targeting the EGFR pathway is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate. This program has completed a Phase 1 clinical trial and has commenced Phase 2a clinical trials in EGFR overexpressing solid tumors. For more information, please visit www.forbius.com.